Chegg Surges 20% on Restructuring and Layoff Newsby Mark Eisenberg 18.06.2024Chegg surges 20% post-market as it announces a restructuring plan involving 441 layoffs to refocus on students and streamline operations.
Chipotle Announces Historic 50-for-1 Stock Splitby Mark Eisenberg 18.06.2024Historic Chipotle 50-for-1 stock split: Hold shares by June 18 to benefit. Split aims to make stock accessible; trading on ...
Kansas Eyes Chiefs Move with New Stadium Planby John Darbie 18.06.2024Kansas lawmakers aim to lure the Super Bowl champion Kansas City Chiefs from Missouri with a new stadium plan, reigniting ...
7 Breakthrough Biotech Stocks to Boost Your Portfolio in 2023by Lilu Anderson 18.06.2024"Discover 7 breakthrough biotech stocks poised to boost your portfolio in a sector projected to reach $521.6B by 2033. Learn ...
Sacks Parente Golf Director Purchases 30,833 Sharesby Mark Eisenberg 18.06.2024Sacks Parente Golf sees confidence boost as Director Brett Widney invests $15K, highlighting growth potential despite past stock volatility.
Piper Sandler Reaffirms Ellington With $13 Targetby Mark Eisenberg 18.06.2024"Piper Sandler reaffirms Ellington Financial as 'Overweight' with a $13 price target, citing strategic acquisitions and robust earnings outlook."
Top Stocks to Watch: Best Buy, GameStop, Micron Analysisby Mark Eisenberg 18.06.2024Discover why Best Buy, GameStop, and Micron Technology are stocks to watch this week with upgrades, shareholder buzz, and strong ...
High Tide Reports Growth Amid Cannabis Sector Challengesby Mark Eisenberg 17.06.2024High Tide Inc. reports 5% revenue growth & 111% same-store sales boost amid cannabis sector challenges, thanks to its unique ...
NFT Market Declines 16%, Ethereum Leads with $39.28M Salesby John Darbie 17.06.2024NFT market sees 16% drop, sales at $121.7M. Ethereum leads with $39.28M, Bitcoin drops 45.60%. Notable sales: $587K on Ethereum, ...
Roche’s Hemlibra Battles Fierce Competition Amid Rating Holdby Mark Eisenberg 17.06.2024Roche's Hemlibra braces for fierce competition from Novo Nordisk's mim8, as analysts give mixed ratings and forecasts on Roche's strategic ...